Caribou Biosciences, Inc.

CRBU

CIK 0001619856 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$4M
↑+89.7% +$2Mvs FY2024 (Q4)
Gross Profit
$4M
↑+89.7% +$2Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -62.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.71 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.05x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +89.7% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -1337.6% · trend +31.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2M
investment in PP&E
Stock-based comp (TTM)
$13M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$175M
everything owned
Total liabilities
$53M
everything owed
Stockholders' equity
$122M
shareholder claim

Recent performance · 25 quarters

Revenue↑+89.7% +$2M
$4M
Net Income↑+20.6% +$7M
$-28M
Free Cash Flow↑+82.9% +$558K
$-115K
Operating Margin↑+551.6pts
-1337.6%

Drill down